Kohshi Ueno

This inventor holds 16 USPTO granted patents, plus 2 CIPO patents, primarily in Organic Chemistry. Top assignees: Eisai Company, Limited, Eisai R&d Management Co., Ltd.. Active years: 1993-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kohshi Ueno. Retrieved from https://idiyas.com/inventor/kohshi-ueno

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 16

% Patents Active = 56.3

CIPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 9.4

ph-index = 7

Forward Citations = 259(Granted Patents)

Location History:

Tsukuba, JP (1993 - 2010)
Ibaraki, JP (1998 - 2011)

Company Filing History:

13 out of 677

Eisai Company, Limited

patents

3 out of 530

Eisai R&d Management Co., Ltd.

patents

Years Active: 1993-2011

Loading Chart...

Areas of Expertise:

1,2-Dihydropyridine Compounds

Quinoline Derivatives

Indole Derivatives

Isoquinoline Derivatives

Heterodiazinone Derivatives

Cyclic Amine Derivatives

Piperidine Compounds

Biphenyl Derivatives

Pharmacological Composition

Manufacturing Method

Salt Compounds

Chemical Synthesis

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7939549 - 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof (2011-05-10),

2. 7718807 - Salt of 1,2-dihydropyridine compound (2010-05-18),

3. 7563811 - 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof (2009-07-21),

4. 7071201 - Quinoline derivatives (2006-07-04),

5. 6949571 - 1,2-dihydropyridine compounds, process for preparation of the same and use thereof (2005-09-27),

6. 6875761 - Certain 1,3-disubstituted isoquinoline derivatives (2005-04-05),

7. 6825192 - Heterodiazinone derivatives (2004-11-30),

8. 6790844 - Certain 1,3-disubstituted isoquinoline derivatives (2004-09-14),

9. 6579881 - Indoles (2003-06-17),

10. 6573384 - Process for production of indole derivatives and intermediates therefor (2003-06-03),

11. 6448243 - 1,4-substituted cyclic amine derivatives (2002-09-10),

12. 6340759 - Fused pyridine derivatives (2002-01-22),

13. 6281214 - Biphenyl derivatives (2001-08-28),

14. 5849912 - Biphenyl derivatives (1998-12-15),

15. 5523307 - Cyclic amine and pharmacological composition (1996-06-04),

Title: Kohshi Ueno: Innovator in Pharmaceutical Chemistry

Introduction

Kohshi Ueno is a prominent inventor based in Ibaraki, Japan, known for his significant contributions to pharmaceutical chemistry. With a total of 16 patents to his name, Ueno has made remarkable advancements in the field, particularly in the development of novel compounds.

Latest Patents

One of Ueno's latest patents involves 1,2-dihydropyridine compounds, along with their manufacturing methods and applications. This invention presents a novel compound that exhibits excellent AMPA receptor inhibitory action and/or kainate inhibitory action. The compound is represented by a specific formula, where Q can be NH, O, or S, and R can vary, indicating hydrogen atoms, halogen atoms, or various alkyl groups. Additionally, Ueno has developed an acid addition salt of a specific 1,2-dihydropyridine compound, which includes various acids such as benzenesulfonic acid and hydrochloric acid.

Career Highlights

Throughout his career, Kohshi Ueno has worked with notable companies, including Eisai Company, Limited and Eisai R&D Management Co., Ltd. His work in these organizations has allowed him to focus on innovative research and development in the pharmaceutical sector.

Collaborations

Ueno has collaborated with several talented individuals in his field, including Koki Kawano and Noritaka Kitazawa. These collaborations have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Kohshi Ueno's contributions to pharmaceutical chemistry through his innovative patents and collaborations highlight his importance in the field. His work continues to influence the development of new therapeutic compounds, showcasing the impact of his inventions on modern medicine.

Profile summary based on public USPTO records.